止咳平喘方联合参麦注射液对支气管哮喘急性发作期患者肺功能和炎症相关因子水平的影响  

Effect of Zhike Pingchuan Formula combined with Shenmai injection on pulmonary function and inflammation-related factors in patients with acute attack of bronchial asthma

作　　者：黄彬[1] 刘纪宁[1] 刘丹[1] 付娟娟 HUANG Bin;LIU Jining;LIU Dan;FU Juanjuan(Department of Emergency Medicine,Mianyang Central Hospital,Mianyang,Sichuan 621000)

机构地区：[1]四川省绵阳市中心医院急诊医学科,四川绵阳621000

出　　处：《河北中医》2022年第7期1107-1110,1114,共5页Hebei Journal of Traditional Chinese Medicine

摘　　要：目的观察止咳平喘方联合参麦注射液对支气管哮喘急性发作期患者肺功能和炎症相关因子水平的影响。方法选取支气管哮喘急性发作期患者114例,按照随机数字表法分为2组,2组均予常规治疗,对照组57例加参麦注射液治疗7 d,治疗组57例在对照组治疗基础上加用止咳平喘方治疗4周。比较2组治疗前、治疗7 d炎症相关因子嗜酸性粒细胞趋化因子(Eotaxin)、转化生长因子β(TGF-β)、肿瘤坏死因子α(TNF-α)、白细胞介素4(IL-4)、白细胞介素33(IL-33)水平,肺功能指标第1 s用力呼气容积(FEV)、FEV/用力肺活量(FVC)、最大自主通气量(MVV)占预计值的百分比(MVV%)、呼气流速峰值(PEFR),比较2组治疗前及治疗4周哮喘控制问卷(ACQ)评分,治疗4周统计比较2组临床疗效。电话或门诊随访6个月,记录患者哮喘急性发作次数和平均住院时间。结果治疗组总有效率94.74%(54/57),对照组总有效率80.70%(46/57),治疗组总有效率高于对照组(P<0.05)。治疗7 d,2组Eotaxin、TGF-β、TNF-α、IL-4、IL-33水平均较本组治疗前降低(P<0.05),且治疗组均低于对照组(P<0.05)。治疗7 d,2组FEV、FEV/FVC、MVV%、PEFR均较本组治疗前升高(P<0.05),且治疗组均高于对照组(P<0.05)。治疗4周2组ACQ评分均较本组治疗前降低(P<0.05),且治疗组低于对照组(P<0.05)。6个月内治疗组急性发作次数少于对照组(P<0.05),平均住院时间短于对照组(P<0.05)。结论止咳平喘方联合参麦注射液治疗支气管哮喘急性发作期可有效改善患者肺功能,控制哮喘,减少复发,可能与降低炎症相关因子水平有关。Objective To observe the effect of Zhike Pingchuan Formula combined with Shenmai injection on pulmonary function and inflammation-related factors in patients with acute attack of bronchial asthma.Methods Totally 114 patients with acute attack of bronchial asthma were randomly divided into two groups,57 cases in each group;in addition to conventional therapy,the control group was treated with Shenmai injection for 7 days,and the treatment group additionally received Zhike Pingchuan Formula for 4 weeks based on the control group.The aim was to compare inflammation-related factors(chemokines[Eotaxin],transforming growth factorβ[TGF-β],tumor necrosis factor-α[TNF-α],interleukin-4[IL-4],interleukin-33[IL-33]),pulmonary function index(Forced expiratory volume in one second[FEV],FEV/forced vital capacity[FVC],predicted value for maximal ventilator volume[MVV%],peak expiratory flow rate[PEFR])on day 0 and on day 7;asthma control questionnaire(ACQ)score on day 0 and on week 4,clinical efficacy on week 4.A 6-month telephone or outpatient follow-up was performed to record the number of asthma onset,average length of stay(ALOS)per admission.Results The overall effective rate was higher in the treatment group(94.74%[54/57])compared with the control group(80.70%[46/57]),(P<0.05).Compared with before treatment,Eotaxin,TGF-β,TNF-α,IL-4,IL-33 on day 7 in groups were decreased(P<0.05),the reduction in the treatment group was more prevalent(P<0.05);FEV,FEV/FVC,MVV%,PEFR in groups were increased(P<0.05),the treatment group was more common(P<0.05);ACQ scores in groups were decreased(P<0.05),which in the treatment group were decreased in comparison with the control group(P<0.05);lower number of asthma onset on month 6,and shorter ALOS per admission were detected in the treatment group than those in the control group(all P<0.05).Conclusion For patients with acute attack of bronchial asthma,Zhike Pingchuan Formula combined with Shenmai injection can effectively improve pulmonary function,control asthma,and reduce recurrence by red

关 键 词：哮喘 中药疗法 止咳平喘 参麦注射液 呼吸功能试验 炎症 

分 类 号：R562.250.531[医药卫生—呼吸系统]